Home › Funds › ArchPoint Investors › RGNX

ArchPoint Investors position in RGNX

REGENXBIO INC · Health Care

ArchPoint Investors reported holding 216,803 shares of RGNX (REGENXBIO INC) in its Q3 2026 13F filing — a position valued at US$1.6M, representing 0.35% of its reported portfolio and ranking #47 among its reported holdings. ArchPoint Investors has disclosed RGNX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)216.80K sh
Reported value held$1.63M
Portfolio Weight0.35%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How ArchPoint Investors's RGNX position evolved

ArchPoint Investors first disclosed a stake in RGNX in Q3 2023 at 224,278 shares (US$3.7M). The position peaked in Q1 2024 at 224,278 shares, worth US$4.7M. Across 13 filings, ArchPoint Investors increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 216,803 shares valued at US$1.6M — a reduction of -5,475 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 224.28K $3.69M New
Q4 2023 224.28K $4.03M Hold
Q1 2024 224.28K $4.73M Hold
Q2 2024 224.28K $2.62M Hold
Q3 2024 224.28K $2.35M Hold
Q4 2024 221.53K $1.71M Reduce
Q1 2025 221.53K $1.58M Hold
Q2 2025 220.53K $1.81M Hold
Q3 2025 223.53K $2.16M Add
Q4 2025 222.28K $3.20M Reduce
Q1 2026 222.28K $1.86M Hold
Q2 2026 222.28K $2.66M Hold
Q3 2026 216.80K $1.63M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RGNX and 13F data

RGNX (REGENXBIO INC) is a Health Care company. 29 other funds we track also report a position in RGNX — the largest reported positions include Redmile Group, LLC (US$52.3M), 22NW, LP (US$5.9M), Pale Fire Capital SE (US$5.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RGNX

All RGNX fund holders →

FAQ

How long has ArchPoint Investors held RGNX?

ArchPoint Investors has disclosed RGNX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is ArchPoint Investors's current position in RGNX?

As of Q3 2026, ArchPoint Investors holds 216.80K shares of RGNX (REGENXBIO INC), valued at $1.63M, representing 0.35% of its reported portfolio and ranking #47.

Has ArchPoint Investors been buying or selling RGNX?

In the latest 13F filing (Q3 2026), ArchPoint Investors reduced its position in RGNX. The position peaked in Q1 2024 at 224.28K shares.

Which other funds hold RGNX?

Other major institutional holders of RGNX include Redmile Group, LLC, 22NW, LP, Pale Fire Capital SE, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.